The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Circulating Tumor Cell-Global Market Insights and Sales Trends 2024
Synopsis
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
The global Circulating Tumor Cell market size is expected to reach US$ 4297.5 million by 2029, growing at a CAGR of 15.0% from 2023 to 2029. The market is mainly driven by the significant applications of Circulating Tumor Cell in various end use industries. The expanding demands from the Breast Cancer, Prostate Cancer, Colorectal Cancer and Others, are propelling Circulating Tumor Cell market. CTC Enrichment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CTC Detection segment is estimated at % CAGR for the next seven-year period.
Global Circulating Tumor Cells main players are Menarini-Silicon Biosystems, Qiagen（Adnagen）, Clearbridge Biomedics, Celsee, Fluidigm. Global top five manufacturers hold a share over 30%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Circulating Tumor Cell, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Circulating Tumor Cell market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Circulating Tumor Cell market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Circulating Tumor Cell sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Circulating Tumor Cell covered in this report include Menarini-Silicon Biosystems, Qiagen（Adnagen）, Clearbridge Biomedics, Celsee, Fluidigm, ApoCell, Greiner Bio-one, Advanced Cell Diagnostics and Aviva Biosciences, etc.
The global Circulating Tumor Cell market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Menarini-Silicon Biosystems
Qiagen（Adnagen）
Clearbridge Biomedics
Celsee
Fluidigm
ApoCell
Greiner Bio-one
Advanced Cell Diagnostics
Aviva Biosciences
Fluxion Biosciences
Sysmex
Epic Sciences
Cynvenio
CytoTrack
Ikonisys
Vortex BioSciences
Gilupi
Biocept
ScreenCell
ANGLE
Global Circulating Tumor Cell market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Circulating Tumor Cell market, Segment by Type:
CTC Enrichment
CTC Detection
CTC Analysis
Global Circulating Tumor Cell market, by Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Circulating Tumor Cell companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
The global Circulating Tumor Cell market size is expected to reach US$ 4297.5 million by 2029, growing at a CAGR of 15.0% from 2023 to 2029. The market is mainly driven by the significant applications of Circulating Tumor Cell in various end use industries. The expanding demands from the Breast Cancer, Prostate Cancer, Colorectal Cancer and Others, are propelling Circulating Tumor Cell market. CTC Enrichment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CTC Detection segment is estimated at % CAGR for the next seven-year period.
Global Circulating Tumor Cells main players are Menarini-Silicon Biosystems, Qiagen（Adnagen）, Clearbridge Biomedics, Celsee, Fluidigm. Global top five manufacturers hold a share over 30%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Circulating Tumor Cell, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Circulating Tumor Cell market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Circulating Tumor Cell market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Circulating Tumor Cell sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Circulating Tumor Cell covered in this report include Menarini-Silicon Biosystems, Qiagen（Adnagen）, Clearbridge Biomedics, Celsee, Fluidigm, ApoCell, Greiner Bio-one, Advanced Cell Diagnostics and Aviva Biosciences, etc.
The global Circulating Tumor Cell market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Menarini-Silicon Biosystems
Qiagen（Adnagen）
Clearbridge Biomedics
Celsee
Fluidigm
ApoCell
Greiner Bio-one
Advanced Cell Diagnostics
Aviva Biosciences
Fluxion Biosciences
Sysmex
Epic Sciences
Cynvenio
CytoTrack
Ikonisys
Vortex BioSciences
Gilupi
Biocept
ScreenCell
ANGLE
Global Circulating Tumor Cell market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Circulating Tumor Cell market, Segment by Type:
CTC Enrichment
CTC Detection
CTC Analysis
Global Circulating Tumor Cell market, by Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Circulating Tumor Cell companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Circulating Tumor Cell
1.1 Circulating Tumor Cell Market Overview
1.1.1 Circulating Tumor Cell Product Scope
1.1.2 Circulating Tumor Cell Market Status and Outlook
1.2 Global Circulating Tumor Cell Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Circulating Tumor Cell Market Size by Region (2018-2029)
1.4 Global Circulating Tumor Cell Historic Market Size by Region (2018-2023)
1.5 Global Circulating Tumor Cell Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Circulating Tumor Cell Market Size (2018-2029)
1.6.1 North America Circulating Tumor Cell Market Size (2018-2029)
1.6.2 Europe Circulating Tumor Cell Market Size (2018-2029)
1.6.3 Asia-Pacific Circulating Tumor Cell Market Size (2018-2029)
1.6.4 Latin America Circulating Tumor Cell Market Size (2018-2029)
1.6.5 Middle East & Africa Circulating Tumor Cell Market Size (2018-2029)
2 Circulating Tumor Cell Market by Type
2.1 Introduction
2.1.1 CTC Enrichment
2.1.2 CTC Detection
2.1.3 CTC Analysis
2.2 Global Circulating Tumor Cell Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Circulating Tumor Cell Historic Market Size by Type (2018-2023)
2.2.2 Global Circulating Tumor Cell Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Circulating Tumor Cell Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Circulating Tumor Cell Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Circulating Tumor Cell Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Circulating Tumor Cell Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Circulating Tumor Cell Revenue Breakdown by Type (2018-2029)
3 Circulating Tumor Cell Market Overview by Application
3.1 Introduction
3.1.1 Breast Cancer
3.1.2 Prostate Cancer
3.1.3 Colorectal Cancer
3.1.4 Others
3.2 Global Circulating Tumor Cell Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Circulating Tumor Cell Historic Market Size by Application (2018-2023)
3.2.2 Global Circulating Tumor Cell Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Circulating Tumor Cell Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Circulating Tumor Cell Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Circulating Tumor Cell Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Circulating Tumor Cell Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Circulating Tumor Cell Revenue Breakdown by Application (2018-2029)
4 Circulating Tumor Cell Competition Analysis by Players
4.1 Global Circulating Tumor Cell Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Circulating Tumor Cell as of 2022)
4.3 Date of Key Players Enter into Circulating Tumor Cell Market
4.4 Global Top Players Circulating Tumor Cell Headquarters and Area Served
4.5 Key Players Circulating Tumor Cell Product Solution and Service
4.6 Competitive Status
4.6.1 Circulating Tumor Cell Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Menarini-Silicon Biosystems
5.1.1 Menarini-Silicon Biosystems Profile
5.1.2 Menarini-Silicon Biosystems Main Business
5.1.3 Menarini-Silicon Biosystems Circulating Tumor Cell Products, Services and Solutions
5.1.4 Menarini-Silicon Biosystems Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.1.5 Menarini-Silicon Biosystems Recent Developments
5.2 Qiagen（Adnagen）
5.2.1 Qiagen（Adnagen） Profile
5.2.2 Qiagen（Adnagen） Main Business
5.2.3 Qiagen（Adnagen） Circulating Tumor Cell Products, Services and Solutions
5.2.4 Qiagen（Adnagen） Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.2.5 Qiagen（Adnagen） Recent Developments
5.3 Clearbridge Biomedics
5.3.1 Clearbridge Biomedics Profile
5.3.2 Clearbridge Biomedics Main Business
5.3.3 Clearbridge Biomedics Circulating Tumor Cell Products, Services and Solutions
5.3.4 Clearbridge Biomedics Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.3.5 Celsee Recent Developments
5.4 Celsee
5.4.1 Celsee Profile
5.4.2 Celsee Main Business
5.4.3 Celsee Circulating Tumor Cell Products, Services and Solutions
5.4.4 Celsee Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.4.5 Celsee Recent Developments
5.5 Fluidigm
5.5.1 Fluidigm Profile
5.5.2 Fluidigm Main Business
5.5.3 Fluidigm Circulating Tumor Cell Products, Services and Solutions
5.5.4 Fluidigm Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.5.5 Fluidigm Recent Developments
5.6 ApoCell
5.6.1 ApoCell Profile
5.6.2 ApoCell Main Business
5.6.3 ApoCell Circulating Tumor Cell Products, Services and Solutions
5.6.4 ApoCell Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.6.5 ApoCell Recent Developments
5.7 Greiner Bio-one
5.7.1 Greiner Bio-one Profile
5.7.2 Greiner Bio-one Main Business
5.7.3 Greiner Bio-one Circulating Tumor Cell Products, Services and Solutions
5.7.4 Greiner Bio-one Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.7.5 Greiner Bio-one Recent Developments
5.8 Advanced Cell Diagnostics
5.8.1 Advanced Cell Diagnostics Profile
5.8.2 Advanced Cell Diagnostics Main Business
5.8.3 Advanced Cell Diagnostics Circulating Tumor Cell Products, Services and Solutions
5.8.4 Advanced Cell Diagnostics Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.8.5 Advanced Cell Diagnostics Recent Developments
5.9 Aviva Biosciences
5.9.1 Aviva Biosciences Profile
5.9.2 Aviva Biosciences Main Business
5.9.3 Aviva Biosciences Circulating Tumor Cell Products, Services and Solutions
5.9.4 Aviva Biosciences Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.9.5 Aviva Biosciences Recent Developments
5.10 Fluxion Biosciences
5.10.1 Fluxion Biosciences Profile
5.10.2 Fluxion Biosciences Main Business
5.10.3 Fluxion Biosciences Circulating Tumor Cell Products, Services and Solutions
5.10.4 Fluxion Biosciences Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.10.5 Fluxion Biosciences Recent Developments
5.11 Sysmex
5.11.1 Sysmex Profile
5.11.2 Sysmex Main Business
5.11.3 Sysmex Circulating Tumor Cell Products, Services and Solutions
5.11.4 Sysmex Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.11.5 Sysmex Recent Developments
5.12 Epic Sciences
5.12.1 Epic Sciences Profile
5.12.2 Epic Sciences Main Business
5.12.3 Epic Sciences Circulating Tumor Cell Products, Services and Solutions
5.12.4 Epic Sciences Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.12.5 Epic Sciences Recent Developments
5.13 Cynvenio
5.13.1 Cynvenio Profile
5.13.2 Cynvenio Main Business
5.13.3 Cynvenio Circulating Tumor Cell Products, Services and Solutions
5.13.4 Cynvenio Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.13.5 Cynvenio Recent Developments
5.14 CytoTrack
5.14.1 CytoTrack Profile
5.14.2 CytoTrack Main Business
5.14.3 CytoTrack Circulating Tumor Cell Products, Services and Solutions
5.14.4 CytoTrack Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.14.5 CytoTrack Recent Developments
5.15 Ikonisys
5.15.1 Ikonisys Profile
5.15.2 Ikonisys Main Business
5.15.3 Ikonisys Circulating Tumor Cell Products, Services and Solutions
5.15.4 Ikonisys Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.15.5 Ikonisys Recent Developments
5.16 Vortex BioSciences
5.16.1 Vortex BioSciences Profile
5.16.2 Vortex BioSciences Main Business
5.16.3 Vortex BioSciences Circulating Tumor Cell Products, Services and Solutions
5.16.4 Vortex BioSciences Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.16.5 Vortex BioSciences Recent Developments
5.17 Gilupi
5.17.1 Gilupi Profile
5.17.2 Gilupi Main Business
5.17.3 Gilupi Circulating Tumor Cell Products, Services and Solutions
5.17.4 Gilupi Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.17.5 Gilupi Recent Developments
5.18 Biocept
5.18.1 Biocept Profile
5.18.2 Biocept Main Business
5.18.3 Biocept Circulating Tumor Cell Products, Services and Solutions
5.18.4 Biocept Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.18.5 Biocept Recent Developments
5.19 ScreenCell
5.19.1 ScreenCell Profile
5.19.2 ScreenCell Main Business
5.19.3 ScreenCell Circulating Tumor Cell Products, Services and Solutions
5.19.4 ScreenCell Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.19.5 ScreenCell Recent Developments
5.20 ANGLE
5.20.1 ANGLE Profile
5.20.2 ANGLE Main Business
5.20.3 ANGLE Circulating Tumor Cell Products, Services and Solutions
5.20.4 ANGLE Circulating Tumor Cell Revenue (US$ Million) & (2018-2023)
5.20.5 ANGLE Recent Developments
6 North America
6.1 North America Circulating Tumor Cell Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Circulating Tumor Cell Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cell Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Circulating Tumor Cell Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cell Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Circulating Tumor Cell Market Dynamics
11.1 Circulating Tumor Cell Industry Trends
11.2 Circulating Tumor Cell Market Drivers
11.3 Circulating Tumor Cell Market Challenges
11.4 Circulating Tumor Cell Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
